MRI-guided radiotherapy for rectal cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The TNTRect trial is a prospective observational study aimed at evaluating the effectiveness of MR-guided stereotactic body radiotherapy (SBRT) for patients with locally advanced rectal cancer. Participants will receive a hypofractionated treatment consisting of 5 daily sessions of 5 Gy, with a simultaneous integrated boost to the tumor. The study will assess patient responses through endoscopy, MRI, and pathology reports, while also measuring local control, disease-free survival, overall survival, and quality of life. The goal is to enhance the complete clinical response rate and promote organ-preserving treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Locally advanced rectal cancer

Exclusion Criteria:

* Patients with unresectable metastatic disease at diagnosis
* Patients with an ECOG performance status \> 2
* Patients not deemed fit for radiotherapy, chemotherapy or surgery

Where it's running

• UZ Brussel - Dienst Radiotherapie
  Jette, Brussels Capital, Belgium Recruiting

Study contacts

• Principal investigator: Mark De Ridder, MD — Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel
• Study coordinator: Mark De Ridder, MD
• Email: mark.deridder@uzbrussel.be
• Phone: 00324776041

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single vs. double stapling and purse-string techniques after rectal cancer surgery

  This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.

  Recruiting Alexandria University · Alexandria · NCT07929415

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• Rectal cancer registry to track real-world treatments and outcomes

  This registry collects real-world data on how locally advanced rectal cancer is treated in Austria, to see how TNT and dMMR/MSI-H cases are managed and what outcomes occur.

  Recruiting at 2 sites Austrian Breast & Colorectal Cancer Study Group · Wiener Neustadt, Lower Austria and 5 other locations · NCT07780305

• Aerobic exercise and guided imagery for bowel problems after rectal cancer surgery

  This study tests whether a program of aerobic exercise plus guided imagery helps people with low anterior resection syndrome after rectal cancer surgery.

  Recruiting Biruni University · Istanbul · NCT07732894

• Active surveillance vs chemoradiotherapy after local removal of intermediate-risk T1 rectal cancer

  This study tests whether close follow-up alone after local removal of early rectal cancer can match the cancer control of adding chemoradiotherapy, while reducing treatment-related side effects.

  Recruiting at 2 sites Medical University of Gdansk · Limoges and 2 other locations · NCT07669298

• Different-Dose Short-Course Radiotherapy With CAPOX, PD-1 Blockade, and IL-2 in Locally Advanced Rectal Cancer

  This phase II trial tests whether a low-dose short-course radiotherapy combined with CAPOX, a PD-1 blocker, and IL-2 works as well as the standard-dose short-course approach in patients with locally advanced rectal cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07646639

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.